Real-world data results:
Switching to Velphoro made a world of difference
Full results below
Double the percentage of patients achieved goal with half the pill burden1
Recently published real-world data shows 6 months after switching to Velphoro, significantly more patients achieved KDOQI goal, with half the pill burden.
Consider a different approach to phosphorus management
A retrospective analysis of pharmacy data assessed the real-world effectiveness of Velphoro in 1,029 adult in-center hemodialysis patients who were switched to Velphoro during routine care between April 2014 through March 2015. The blinded study compared the proportion of patients with phosphorus levels <5.5 mg/dL and the mean prescribed PB pills/day at baseline (3 months prior to Velphoro) and during Velphoro follow-up (6 months after switch to Velphoro, n=424). This was a non-interventional analysis and did not impact prescriptions or prescribing patterns.
Regardless of prior therapy, a switch to Velphoro doubled the percentage of patients who achieved goal at 6 months.1
Create a world of difference for your patients with a switch to Velphoro
Read the details of this real world data analysis on phosphorus control and reduced pill burden with Velphoro
Read the article
Velphoro is flexible and affordable for your patients
Starting dose of 1 tablet per meal. Easy to chew and
See the options
easy to crush.2
Velphoro Access Solutions
Coverage is available on most national Medicare Part D and commercial plans.
- Coyne DW, Ficociello LH, Parameswaran V, et al. Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data. Clin Nephrol. 2017;88(2):59-67.
- Velphoro® [package insert]. Waltham, MA: Fresenius Medical Care North America; 2018.
Velphoro® (sucroferric oxyhydroxide) is a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.
IMPORTANT SAFETY INFORMATION
- Velphoro must be administered with meals. Velphoro tablets must be chewed and not swallowed whole. To aid with chewing and swallowing, the tablets may be crushed.
- Patients with peritonitis during peritoneal dialysis, significant gastric or hepatic disorders, following major gastrointestinal (GI) surgery, or with a history of hemochromatosis or other diseases with iron accumulation have not been included in clinical studies with Velphoro. Monitor effect and iron homeostasis in such patients.
- In a parallel design, fixed-dose study of 6 weeks duration, the most common adverse drug reactions to Velphoro chewable tablets in hemodialysis patients included discolored feces (12%) and diarrhea (6%).
- Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMG-CoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. Take doxycycline at least 1 hour before Velphoro. Velphoro should not be prescribed with oral levothyroxine.
For additional important safety information, please see the full Prescribing Information.
To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Medical Care North America at
1-800-323-5188 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
This information is intended for use by US healthcare professionals only.
Fresenius Medical Care North America
Waltham, MA 02451